Initially founded as a cancer vaccines company in 2015, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19.

Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.